IMMUNOLOGICAL AND CLINICAL-RESPONSE TO IMMUNOSUPPRESSIVE TREATMENT IN PARANEOPLASTIC CEREBELLAR DEGENERATION

被引:50
|
作者
STARK, E
WURSTER, U
PATZOLD, U
SAILER, M
HAAS, J
机构
[1] HANNOVER MED SCH,DEPT NEUROL,HANNOVER,GERMANY
[2] MUNICIPAL HOSP BRAUNSCHWEIG,NEUROL CLIN,BRAUNSCHWEIG,GERMANY
关键词
D O I
10.1001/archneur.1995.00540320098016
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To report the clinical and immunological response to immunosuppressive treatment with cyclophosphamide in two patients with paraneoplastic cerebellar degeneration. Design: Case reports. Clinical and immunological follow-up data were available for 4 1/2 years in the first patient and for 2 years in the second patient. Setting: A 1500-bed university hospital and a 1200-bed university teaching hospital. Intervention: Cyclophosphamide intermittent treatment. Main Outcome Measure: Clinical disability. Results: One of the patients, who was treated from an early stage, recovered completely, The other patient showed a partial clinical response. While the two patients were receiving a maintenance regimen with cyclophosphamide, the conditions of both patients remained stable for at least 2 years. In both patients, intrathecal antibody synthesis declined considerably. Conclusion: Early induction of immunosuppressive therapy with cyclophosphamide should be tried in treating patients with paraneoplastic cerebellar degeneration.
引用
收藏
页码:814 / 818
页数:5
相关论文
共 50 条
  • [1] Autoimmune paraneoplastic cerebellar degeneration -: Clinical and immunological analysis
    Stourac, P
    Dolezil, D
    Kavpilová, K
    Kadanka, Z
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2000, 63 (02) : 97 - 101
  • [2] Treatment of Paraneoplastic Cerebellar Degeneration
    John E. Greenlee
    Current Treatment Options in Neurology, 2013, 15 : 185 - 200
  • [3] Treatment of Paraneoplastic Cerebellar Degeneration
    Greenlee, John E.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2013, 15 (02) : 185 - 200
  • [4] Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications
    Yshii, Lidia
    Bost, Chloe
    Liblau, Roland
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [5] Clinical insights into paraneoplastic cerebellar degeneration
    Scheid, R
    Voltz, R
    Briest, S
    Kluge, R
    von Cramon, DY
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2006, 77 (04): : 529 - 530
  • [6] Clinical characteristics of patients with paraneoplastic cerebellar degeneration
    Xu, Z.
    Tan, L. C.
    MOVEMENT DISORDERS, 2015, 30 : S371 - S371
  • [7] Successful treatment of paraneoplastic cerebellar degeneration with Rituximab
    Marcello Esposito
    P. Penza
    G. Orefice
    A. Pagano
    E. Parente
    A. Abbadessa
    V. Bonavita
    Journal of Neuro-Oncology, 2008, 86 : 363 - 364
  • [8] Successful treatment of paraneoplastic cerebellar degeneration with Rituximab
    Esposito, Marcello
    Penza, P.
    Orefice, G.
    Pagano, A.
    Parente, E.
    Abbadessa, A.
    Bonavita, V.
    JOURNAL OF NEURO-ONCOLOGY, 2008, 86 (03) : 363 - 364
  • [9] PARANEOPLASTIC CEREBELLAR DEGENERATION
    EPISTEME, S
    CANCER JOURNAL - FRANCE, 1991, 4 (01): : 9 - 9
  • [10] Paraneoplastic cerebellar degeneration
    Huober, J
    Niedermaier, N
    Drlicek, M
    Kaufmann, M
    Hacke, W
    Bastert, G
    GEBURTSHILFE UND FRAUENHEILKUNDE, 1996, 56 (04) : 214 - 216